首页> 美国卫生研究院文献>Cancer Science >Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients
【2h】

Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients

机译:丝氨酸蛋白酶抑制剂9可以被上皮癌患者的细胞毒性T淋巴细胞识别

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Serine proteinase inhibitor 9 (PI–9) inhibits granzyme B‐mediated apoptosis and interleukin–lβ‐converting enzyme activity. In this study, we report that the PI–9 gene encodes antigenic epitopes recognized by the HLA‐A24–restricted and tumor‐reactive cytotoxic T lymphocytes (CTLs) of epithelial cancer patients. Screening of an autologous cDNA library using a CTL line recognizing HLA‐A24+ tumor cells resulted in the isolation of a cDNA, which had an identical coding region to the previously described PI–9 genes. PI–9 gene was expressed in approximately three‐fourths of epithelial cancer cell lines and all leukemic cell lines tested. It was also expressed in normal peripheral blood mononuclear cells (PBMCs), but not in a normal fibroblast cell line. CTL sublines contained T cells capable of recognizing the PI–9292–300 and PI–9348–356 peptides among 13 different peptides having the HLA‐A24 binding motifs. These two peptides were recognized by the CTL line in a dose‐dependent and HLA class‐I‐restricted manner, and also possessed the ability to induce HLA class I‐restricted and tumor‐reactive CTLs in PBMCs from HLA‐A24+ cancer patients. These results demonstrate that PI–9 is recognized by HLA class I‐restricted and tumor‐reactive CTLs of epithelial cancer patients.
机译:丝氨酸蛋白酶抑制剂9(PI-9)抑制粒酶B介导的凋亡和白介素-lβ转化酶的活性。在这项研究中,我们报告PI-9基因编码被上皮癌患者的HLA-A24限制性和肿瘤反应性细胞毒性T淋巴细胞(CTL)识别的抗原表位。使用识别HLA-A24 + 肿瘤细胞的CTL品系筛选自体cDNA文库,导致分离出cDNA,该cDNA具有与先前描述的PI-9基因相同的编码区。 PI–9基因在约四分之三的上皮癌细胞系和所有白血病细胞系中表达。它也在正常的外周血单核细胞(PBMC)中表达,但在正常的成纤维细胞系中不表达。 CTL子系包含能够识别具有HLA-A24结合基序的13种不同肽中的PI–9292–300和PI–9348–356肽的T细胞。这两种肽以剂量依赖性和HLA I类限制的方式被CTL系识别,并且还具有从HLA-A24 +诱导PBMC中HLA I类限制和肿瘤反应性CTL的能力。 癌症患者。这些结果表明,PI–9被上皮癌患者的HLA I类限制和肿瘤反应性CTL识别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号